Literature DB >> 193662

Smooth muscle antibody in Burkitt's lymphoma and in nasopharyngeal carcinoma.

J P Lamelin, E H Williams, T Souissi, G De-Thé, G Gabbiani.   

Abstract

Smooth muscle antibodies (SMA) with specificity for actin, were found with a higher frequency in sera from Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (NPC) patients than in sera from matched controls. No correlation could be found between SMA and anti-Epstein-Barr virus (EBV) antibody titres. There was no parallelism, in individual sera, between the finding of SMA and the occurrence of cold lymphocytotoxins, aother antibody activity found with an abnormally high frequency among BL and NPC patients. The reason why actin, a weak antigen in experimental animals, may become immunogenic in humans remains unexplained.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 193662      PMCID： PMC1540865     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  17 in total

1.  Reactivity of smooth-muscle antibodies, surface ultrastructure, and mobility in cells of human hematopoietic cell lines.

Authors:  A Fagraeus; K Nilsson; K Lidman; R Norberg
Journal:  J Natl Cancer Inst       Date:  1975-10       Impact factor: 13.506

2.  Detection and ultrastructural localization of human smooth muscle myosin-like molecules in human non-muscle cells by specific antibodies.

Authors:  R G Painter; M Sheetz; S J Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

3.  Smooth-muscle antibodies and antibodies to cytomegalovirus and Epstein-Barr virus in leukaemias and lymphomata.

Authors:  P Andersen; J Molgaard; I Andersen; H K Andersen
Journal:  Acta Pathol Microbiol Scand C       Date:  1976-04

4.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

5.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

6.  Reaction of human smooth muscle antibody with thymus medullary cells.

Authors:  A Fagraeus; H The; G Biberfeld
Journal:  Nat New Biol       Date:  1973-11-28

Review 7.  Actin and myosin and cell movement.

Authors:  T D Pollard; R R Weihing
Journal:  CRC Crit Rev Biochem       Date:  1974-01

8.  Antibody to smooth muscle in patients with liver disease.

Authors:  G D Johnson; E J Holborow; L E Glynn
Journal:  Lancet       Date:  1965-10-30       Impact factor: 79.321

9.  Human smooth muscle autoantibody. Its identification as antiactin antibody and a study of its binding to "nonmuscular" cells.

Authors:  G Gabbiani; G B Ryan; J P Lamelin; P Vassalli; G Majno; C A Bouvier; A Cruchaud; E F Lüscher
Journal:  Am J Pathol       Date:  1973-09       Impact factor: 4.307

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728
View more
  4 in total

1.  Autoantibodies in three populations of Burkitt's lymphoma patients.

Authors:  E Vainio; G M Lenoir; R M Franklin
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

2.  Different types of smooth muscle antibodies in chronic active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic significance.

Authors:  P Kurki; A Miettinen; E Linder; P Pikkarainen; M Vuoristo; M P Salaspuro
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

Review 3.  Subversion of the actin cytoskeleton during viral infection.

Authors:  Matthew P Taylor; Orkide O Koyuncu; Lynn W Enquist
Journal:  Nat Rev Microbiol       Date:  2011-04-27       Impact factor: 60.633

4.  Antibodies to skeletal muscle actin and their reactivity with malignant melanoma of the choroid.

Authors:  A Malaty; A Rahi; A Garner
Journal:  Br J Ophthalmol       Date:  1980-03       Impact factor: 4.638
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.